Eli Lilly and Company / Akouos Inc.

OTOF-Mediated Sensorineural Hearing Loss

4K US cases/yr · $2.0B Estimated peak global genetic hearing loss gene therapy market · ~1-3/1000 U.S. congenital sensorineural hearing loss incidence

Disease Overview

Sensorineural hearing loss affects approximately 37.5 million U.S. adults; congenital sensorineural hearing loss occurs in roughly 1-3 per 1,000 live births in the United States. OTOF gene mutations cause autosomal recessive sensorineural hearing loss type 9 (DFNB9), characterized by profound prelingual deafness due to defective synaptic transmission at the inner hair cell ribbon synapse. OTOF mutations are estimated to account for 1-8% of congenital severe-to-profound sensorineural hearing loss, translating to approximately 200,000 affected patients globally and several thousand new pediatric cases per year. Until 2023 there was no pharmacologic intervention; cochlear implants represent standard of care, with newborn hearing screening enabling early identification. Akouos's AK-OTOF (now LY3884961) is an AAVAnc80 gene therapy delivering full-length human OTOF cDNA via intracochlear administration. The asset competes within an emerging genetic hearing loss class. The first-in-human dose in October 2023 produced restoration of hearing within 30 days in an 11-year-old patient, validating proof of concept. The commercial opportunity is small-population orphan but represents the foundational AAV payload for a broader inner-ear gene therapy franchise.

Competitive Landscape

The OTOF gene therapy landscape is a young but contested race that emerged into clinical readouts in 2022-2023. AK-OTOF/LY3884961 (AAVAnc80-hOTOF, Eli Lilly via Akouos) reported first-in-human hearing restoration in an 11-year-old patient in October 2023, the first U.S./global pharma-led OTOF clinical readout. DB-OTO (AAV1-hOTOF, Regeneron via Decibel Therapeutics acquisition August 2023) reported positive proof-of-concept data from the CHORD trial showing hearing restoration in pediatric patients in October 2023, days after the Lilly data drop. Sensorion's SENS-501 (AAV-OTOF, French biotech) is in IND-enabling stage with first patient dosing planned. Otovia Therapeutics and Refreshgene (academic Chinese consortium led by Yilai Shu at Eye and ENT Hospital of Fudan University) reported the earliest pediatric hearing restoration data in 2022-2023 with a binaural AAV-OTOF construct, predating Western pharma readouts. Standard of care remains cochlear implantation (Cochlear Ltd., Advanced Bionics/Sonova, MED-EL); these device-based interventions provide functional hearing but bypass biological repair entirely. Lilly's Akouos acquisition is a platform-plus-lead-asset bet that positions Lilly in the inner-ear AAV franchise alongside the Regeneron/Decibel, Sensorion, and Chinese academic consortium competitive set across the 2024-2027 readout window.